Skip to main content
MedicHelpLine
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBARACHNOIDHigh Alert

Bupivacaine Hydrochloride

BUPIVACAINE HYDROCHLORIDE

Standard Dose
2 DOSAGE AND ADMINISTRATION 2.1 Important Dosage and Administration Information Visually inspect this product for particulate matter and discoloration prior to administration. Bupivacaine Hydrochloride in Dextrose Injection, USP is a clear, colorless solution. Do not administer solutions which are discolored or contain particulate matter. Mixing or the prior or intercurrent use of any other local anesthetic with Bupivacaine Hydrochloride in Dextrose Injection, USP is not recommended because of insufficient data on the clinical use of such mixtures. Discard unused portions of Bupivacaine Hydrochloride in Dextrose Injection, USP following initial use. Administration Precautions Bupivacaine Hydrochloride in Dextrose Injection, USP is to be administered in carefully adjusted dosages by or under the supervision of experienced clinicians who are well versed in the diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed. Use Bupivacaine Hydrochloride in Dextrose Injection, USP only if the following are immediately available: oxygen, cardiopulmonary resuscitative equipment and drugs, and the personnel resources needed for proper management of toxic reactions and related emergencies [ see Warnings and Precautions (5.3) , Adverse Reactions (6) , Overdosage (10) ]. The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects related to local anesthetic systemic toxicity when additional local anesthetics are administered with Bupivacaine Hydrochloride in Dextrose Injection, USP [ see Warnings and Precautions (5.3) , Drug Interactions (7.1) , Overdosage (10) ]. Aspirate for blood and cerebrospinal fluid prior to injecting Bupivacaine Hydrochloride in Dextrose Injection, USP, for both the initial dose and all subsequent doses (where applicable), to avoid intravascular injection and to confirm entry into the subarachnoid space. Aspiration of cerebrospinal fluid into a Bupivacaine Hydrochloride in Dextrose Injection, USP-filled syringe will result in an identifiable swirl in the solution. A negative aspiration for blood does not ensure against an intravascular injection [ see Warnings and Precautions (5.4) ]. Avoid rapid injection of Bupivacaine Hydrochloride in Dextrose Injection, USP. The patient should have an indwelling intravenous catheter to assure adequate intravenous access. The lowest dosage of Bupivacaine Hydrochloride in Dextrose Injection, USP that results in effective spinal anesthesia should be used to avoid a high motor block and serious adverse reactions. Perform careful and constant monitoring of cardiovascular and respiratory (adequacy of oxygenation and ventilation) vital signs and the patient’s level of consciousness during spinal anesthesia. Conditions Which May Preclude Use of Spinal Anesthesia The following conditions may preclude the use of spinal anesthesia, depending upon the physician’s evaluation of the patient: Pre-existing diseases of the central nervous system (CNS), such as those attributable to pernicious anemia, poliomyelitis, syphilis, or tumor. Hematological disorders predisposing to coagulopathies or patients on anticoagulant therapy. Trauma to a blood vessel during the conduct of spinal anesthesia may, in some instances, result in uncontrollable CNS hemorrhage, soft tissue hemorrhage, or development of a hematoma. Chronic backache and preoperative headache. Hypotension and hypertension. Technical problems (persistent paresthesias, persistent bloody tap). Arthritis or spinal deformity. Extremes of age. Psychosis, dementia, or other illnesses resulting in poor patient cooperation. 2.2 Recommended Dosages of Bupivacaine Hydrochloride in Dextrose Injection, USP The dosage of Bupivacaine Hydrochloride in Dextrose Injection, USP administered varies with the anesthetic procedure, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of muscle relaxation required, the duration of anesthesia desired, individual tolerance, and the physical condition of the patient. Administer the smallest dosage and concentration required to produce the desired result. The extent and degree of spinal anesthesia depend upon several factors including dosage, baricity of the anesthetic solution, volume of solution, force of injection, level of puncture, and position of the patient during and immediately after injection. In recommended doses, Bupivacaine Hydrochloride in Dextrose Injection, USP produces complete motor and sensory block. The following table summarizes general dosage guidelines for adult patients for the procedures described: PROCEDURES DOSAGE GUIDELINES Vaginal Delivery Starting dose, 6 mg (0.8 mL) Lower Extremity and Perineal Procedures, such as: transurethral resection of the prostate (TURP) vaginal hysterectomy 7.5 mg (1 mL) Lower Abdominal Procedures, such as: abdominal hysterectomy tubal ligation appendectomy 12 mg (1.6 mL) Cesarean Section 7.5 mg to 10.5 mg (1 mL to 1.4 mL)
Max Dose
See official label
Primary Use
1 INDICATIONS AND USAGE Bupivacaine Hydrochloride in Dextrose Injection, USP is indicated for subarachnoid injection in adults for the production of subarachnoid block (spinal anesthesia).
Summary

Indications and usage 1 INDICATIONS AND USAGE Bupivacaine Hydrochloride in Dextrose Injection, USP is indicated for subarachnoid injection in adults for the production of subarachnoid block (spinal anesthesia).

Dosage and administration 2 DOSAGE AND ADMINISTRATION 2.1 Important Dosage and Administration Information Visually inspect this product for particulate matter and discoloration prior to administration.

Structured Monograph

Clinical summary

Indications and usage 1 INDICATIONS AND USAGE Bupivacaine Hydrochloride in Dextrose Injection, USP is indicated for subarachnoid injection in adults for the production of subarachnoid block (spinal anesthesia). Dosage and administration 2 DOSAGE AND ADMINISTRATION 2.1 Important Dosage and Administration Information Visually inspect this product for particulate matter and discoloration prior to administration. Bupivacaine Hydrochloride in Dextrose Injection, USP is a clear, colorless solution. Do not administer solutions which are discolored or contain particulate matter. Mixing or the prior or intercurrent use of any other local anesthetic with Bupivacaine Hydrochloride in Dextrose Injection, USP is not recommended because of insufficient data on the clinical use of such mixtures. Discard unused portions of Bupivacaine Hydrochloride in Dextrose Injection, USP following initial use. Administration Precautions Bupivacaine Hydrochloride in Dextrose Injection, USP is to be administered in carefully adjusted dosages by or under the supervision of experienced clinicians who are well versed in the diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed. Use Bupivacaine Hydrochloride in Dextrose Injection, USP only if the following are immediately available: oxygen, cardiopulmonary resuscitative equipment and drugs, and the personnel resources needed for proper management of toxic reactions and related emergencies [ see Warnings and Precautions (5.3) , Adverse Reactions (6) , Overdosage (10) ]. The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects related to local anesthetic systemic toxicity when additional local anesthetics are administered with Bupivacaine Hydrochloride in Dextrose Injection, USP [ see Warnings and Precautions (5.3) , Drug Interactions (7.1) , Overdosage (10) ]. Aspirate for blood and cerebrospinal fluid prior to injecting Bupivacaine Hydrochloride in Dextrose Injection, USP, for both the initial dose and all subsequent doses (where applicable), to avoid intravascular injection and to confirm entry into the subarachnoid space. Aspiration of cerebrospinal fluid into a Bupivacaine Hydrochloride in Dextrose Injection, USP-filled syringe will result in an identifiable swirl in the solution. A negative aspiration for blood does not ensure against an intravascular injection [ see Warnings and Precautions (5.4) ]. Avoid rapid injection of Bupivacaine Hydrochloride in Dextrose Injection, USP. The patient should have an indwelling intravenous catheter to assure adequate intravenous access. The lowest dosage of Bupivacaine Hydrochloride in Dextrose Injection, USP that results in effective spinal anesthesia should be used to avoid a high motor block and serious adverse reactions. Perform careful and constant monitoring of cardiovascular and respiratory (adequacy of oxygenation and ventilation) vital signs and the patient’s level of consciousness during spinal anesthesia. Conditions Which May Preclude Use of Spinal Anesthesia The following conditions may preclude the use of spinal anesthesia, depending upon the physician’s evaluation of the patient: Pre-existing diseases of the central nervous system (CNS), such as those attributable to pernicious anemia, poliomyelitis, syphilis, or tumor. Hematological disorders predisposing to coagulopathies or patients on anticoagulant therapy. Trauma to a blood vessel during the conduct of spinal anesthesia may, in some instances, result in uncontrollable CNS hemorrhage, soft tissue hemorrhage, or development of a hematoma. Chronic backache and preoperative headache. Hypotension and hypertension. Technical problems (persistent paresthesias, persistent bloody tap). Arthritis or spinal deformity. Extremes of age. Psychosis, dementia, or other illnesses resulting in poor patient cooperation. 2.2 Recommended Dosages of Bupivacaine Hydrochloride in Dextrose Injection, USP The dosage of Bupivacaine Hydrochloride in Dextrose Injection, USP administered varies with the anesthetic procedure, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of muscle relaxation required, the duration of anesthesia desired, individual tolerance, and the physical condition of the patient. Administer the smallest dosage and concentration required to produce the desired result. The extent and degree of spinal anesthesia depend upon several factors including dosage, baricity of the anesthetic solution, volume of solution, force of injection, level of puncture, and position of the patient during and immediately after injection. In recommended doses, Bupivacaine Hydrochloride in Dextrose Injection, USP produces complete motor and sensory block. The following table summarizes general dosage guidelines for adult patients for the procedures described: PROCEDURES DOSAGE GUIDELINES Vaginal Delivery Starting dose, 6 mg (0.8 mL)

Monitoring

  • 5 WARNINGS AND PRECAUTIONS 5.1 Use of Spinal Anesthetics During Uterine Contractions Spinal anesthetics including Bupivacaine Hydrochloride in Dextrose Injection, USP should not be injected during uterine contractions because cerebrospinal fluid current may carry the drug further cephalad than desired, resulting in a high motor block.
  • 5.2 Patients with Hypertension Sympathetic blockade due to spinal anesthesia may result in peripheral vasodilation and hypotension, the extent of which depends on the number of dermatomes blocked.
  • Patients over 65 years, particularly those with hypertension, may be at increased risk for experiencing the hypotensive effects of Bupivacaine Hydrochloride in Dextrose Injection, USP.
  • Monitor blood pressure frequently, especially in the early phases of anesthesia.

Interaction Notes

  • 7 DRUG INERACTIONS 7.1 Local Anesthetics The toxic effects of local anesthetics are additive.
  • If coadministration of other local anesthetics with Bupivacaine Hydrochloride in Dextrose Injection, USP cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [ see Dosage and Administration (2.1) , Warnings and Precautions (5.3) ].
  • 7.2 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride in Dextrose Injection, USP are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics [ see Warnings and Precautions (5.5) ].
  • Examples of Drugs Associated with Methemoglobinemia: Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine
Bupivacaine Hydrochloride (BUPIVACAINE HYDROCHLORIDE) | Drug Monograph | MedicHelpline